COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

BACKGROUND: We previously summarized outcomes for 46 cladribine tablets (CladT)-treated patients with multiple sclerosis (MS) and confirmed or suspected COVID-19, as reported to the Merck KGaA Global Patient Safety Database. This report updates on these findings, to 15 January 2021, for a total of 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997846/
https://www.ncbi.nlm.nih.gov/pubmed/33813097
http://dx.doi.org/10.1016/j.msard.2021.102929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997846/
https://www.ncbi.nlm.nih.gov/pubmed/33813097
http://dx.doi.org/10.1016/j.msard.2021.102929

Ejemplares similares